OFS Capital Reports 7.52% Net Margin, Analysts See 39.7% Upside to $7 Target
OFS Capital reported a net margin of 7.52%, ROE of 8.95% and ROA of 3.41%, significantly outperforming Advanced Medical Isotope’s -6,144.90% net margin and -113.56% ROA. Analysts assign OFS Capital a $7.00 consensus price target implying 39.7% upside and rate it 1.50 versus RDGL’s 0.00.
1. Profitability and Returns
OFS Capital reported a net margin of 7.52%, return on equity of 8.95%, and return on assets of 3.41% over the most recent fiscal year. These metrics place the firm among the stronger performers in the business development company sector, driven by consistent interest income from its direct and structured debt investments and disciplined expense management.
2. Ownership Structure
Institutional investors hold 10.8% of OFS Capital’s outstanding shares, reflecting confidence from hedge funds, endowments and large money managers in the company’s long-term prospects. Insider ownership stands at 0.5%, indicating that senior executives and directors maintain a modest personal stake in the business’s performance.
3. Analyst Outlook
Analysts following OFS Capital currently assign one Sell rating and one Hold rating, resulting in a rating score of 1.50 on a 4-point scale. The consensus price target of $7.00 implies upside potential of approximately 39.7%, suggesting that, despite mixed near-term views, there is material room for share appreciation according to brokerage forecasts.
4. Valuation and Financial Performance
In the latest reported quarter, OFS Capital generated $47.96 million in gross revenue and net income of $28.44 million, translating to earnings per share of $0.24. The company’s price-to-earnings ratio stands at 20.88, reflecting a valuation in line with mid-market BDC peers. OFS Capital’s beta of 0.85 indicates its shares have historically been 15% less volatile than the S&P 500 index.